The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
The chronic obstructive pulmonary disease (COPD) therapy market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics…
Epi Data Slicer
MARKET OUTLOOKThe severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/…
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in China and, thus, a major public health concern. We expect the Chinese COPD therapy market to experience robust…
Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…